Abstracts at ESTRO 2026

TheraPanacea Announces 16 Accepted Abstracts at ESTRO 2026, Demonstrating a strong innovation pipeline of AI in Radiation Oncology

Paris, France – April 16, 2026 – TheraPanacea today announced that 16 scientific abstracts developed in collaboration with leading cancer centers across Europe and the United States have been accepted for presentation at ESTRO 2026.

These contributions reflect the ambition to bring meaningful AI into everyday radiotherapy practice – supporting clinicians in delivering consistent, high-quality care in increasingly complex environments.

A Continued Focus on Practical Clinical Use

As radiotherapy evolves, so does the role of artificial intelligence. The question is no longer whether AI can perform individual tasks, but how it can be used in a way that is reliable, clinically acceptable, and easy to integrate into existing workflows.

The studies presented at ESTRO 2026 reflect this shift. They focus not only on technical performance, but how AI can support quality routine clinical work – reducing variability, improving efficiency, and helping teams manage growing demands.

Work Spanning the Full Radiotherapy Workflow

The 16 accepted abstracts cover key areas of radiotherapy, including:

• Auto-segmentation, with studies evaluating performance across complex anatomical regions and reinforcing the importance of clinician oversight
• Adaptive radiotherapy, with multiple studies demonstrating strong agreement between AI-generated synthetic CT and planning CT across several indications
• Automated treatment planning, with results showing clinically acceptable plans generated in approximately 10 minutes across prostate, breast, and head and neck workflows
• Emerging approaches, including new methods for dose modeling and exploration of upright radiotherapy

Together, these contributions reflect steady progress toward integrating AI across the full radiotherapy workflow.

Built Through Clinical Collaboration

All studies were developed in close collaboration with clinical partners, including Gustave Roussy, Institut Curie, Centre Léon Bérard, CHU Nîmes, and Penn Medicine.

Working directly with clinicians remains central to TheraPanacea’s approach – ensuring that solutions are shaped by real clinical needs and validated in real-world environments.

A Step Forward, Built Incrementally

“Progress in this field happens step by step,” said Nikos Paragios, CEO of TheraPanacea.

“These studies reflect the work of many teams – clinicians, physicists, and researchers -who are focused on making AI useful in practice. Our goal is not to add complexity, but to help manage it. If we can reduce variability, save time, and support better decisions, then we are moving in the right direction.”

About TheraPanacea

TheraPanacea is a medical technology company developing artificial intelligence solutions for oncology, with a primary focus on radiotherapy. Its software integrates into existing clinical environments to support contouring, treatment planning, and adaptive workflows.

The company works in close collaboration with leading cancer centers, including Gustave Roussy, and its solutions are deployed across more than 230 clinical instances worldwide.

For a Full list of the 2026 ESTRO Accepted Abstracts, click here